132 related articles for article (PubMed ID: 31570463)
1. A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Ozawa H; Sata A; Fukui R; Bun A; Higuchi T; Fujimoto Y; Miyagawa Y; Imamura M; Miyoshi Y
Anticancer Res; 2019 Oct; 39(10):5653-5662. PubMed ID: 31570463
[TBL] [Abstract][Full Text] [Related]
2. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.
He M; Li JJ; Zuo WJ; Ji L; Jiang YZ; Hu XC; Wang ZH; Shao ZM
Cancer Med; 2019 Oct; 8(14):6212-6220. PubMed ID: 31373147
[TBL] [Abstract][Full Text] [Related]
3. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Zhao Y; Li Y; Gong C; Xie Y; Zhang J; Wang L; Cao J; Tao Z; Wang B; Hu X
Cancer Med; 2020 Dec; 9(23):8821-8831. PubMed ID: 33022852
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Blancas I; Fontanillas M; Conde V; Lao J; Martínez E; Sotelo MJ; Jaen A; Bayo JL; Carabantes F; Illarramendi JJ; Gordon MM; Cruz J; García-Palomo A; Mendiola C; Pérez-Ruiz E; Bofill JS; Baena-Cañada JM; Jáñez NM; Esquerdo G; Ruiz-Borrego M
Clin Transl Oncol; 2018 Jul; 20(7):862-869. PubMed ID: 29178019
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Liu J; Li J; Wang H; Wang Y; He Q; Xia X; Hu ZY; Ouyang Q
J Transl Med; 2019 Jan; 17(1):27. PubMed ID: 30646914
[TBL] [Abstract][Full Text] [Related]
6. Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.
Heo MH; Kim HK; Lee H; Kim JY; Ahn JS; Im YH; Park YH
Korean J Intern Med; 2019 Sep; 34(5):1100-1106. PubMed ID: 29540055
[TBL] [Abstract][Full Text] [Related]
7. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
8. Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
Koi Y; Koga C; Akiyoshi S; Masuda T; Ijichi H; Nakamura Y; Ishida M; Ohno S; Tokunaga E
Anticancer Res; 2018 Mar; 38(3):1579-1584. PubMed ID: 29491088
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer.
Skinner KE; Olufade T; Walker MS; Schwartzberg LS
Breast J; 2020 Feb; 26(2):112-119. PubMed ID: 31531938
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of fulvestrant in treating postmenopausal patients with estrogen receptor-positive metastatic breast cancer and prognostic analysis.
Li T; Jiao L
J BUON; 2021; 26(1):189-195. PubMed ID: 33721451
[TBL] [Abstract][Full Text] [Related]
11. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
[TBL] [Abstract][Full Text] [Related]
12. Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Xie Y; Zhao Y; Gong C; Chen Z; Zhang Y; Zhao Y; Yuan P; Hu S; Li Y; Hu X; Zhang J; Wang L; Wang B
Sci Rep; 2019 Feb; 9(1):1710. PubMed ID: 30737426
[TBL] [Abstract][Full Text] [Related]
13. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
du Rusquec P; Palpacuer C; Campion L; Patsouris A; Augereau P; Gourmelon C; Robert M; Dumas L; Caroline F; Campone M; Frenel JS
Breast Cancer Res Treat; 2018 Apr; 168(2):559-566. PubMed ID: 29247442
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series.
Huang J; Huang P; Shao XY; Sun Y; Lei L; Lou CJ; Ye WW; Chen JQ; Cao WM; Huang Y; Zheng YB; Wang XJ; Chen ZH
Medicine (Baltimore); 2020 Jul; 99(29):e20821. PubMed ID: 32702824
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
Araki K; Ishida N; Horii R; Takahashi S; Akiyama F; Ito Y; Ohno S
Expert Opin Pharmacother; 2015; 16(17):2561-8. PubMed ID: 26558799
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Niraula S; Ocana A
Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
